Phase I Trial of Taxotere: Five-Day Schedule

1992134 citationsJournal Article

Authors

Richard Pazdur · The University of Texas MD Anderson Cancer Center

Robert A. Newman · The University of Texas MD Anderson Cancer Center

Beth Newman · The University of Texas MD Anderson Cancer Center

A Fuentes · The University of Texas MD Anderson Cancer Center

John A. Benvenuto · The University of Texas MD Anderson Cancer Center

B. Bready · The University of Texas MD Anderson Cancer Center

Dennis W. Moore

Abstract

Granulocytopenia associated with oral mucositis is the dose-limiting toxicity of this schedule. We recommended a starting dose of 14 mg/m2 per day for phase II studies of this 5-day schedule. Dose modifications on days 2-5 based on the day-1 AUC may allow individualized dosing.

Topics & Keywords

Cancer Treatment and Pharmacology Cancer Genomics and Diagnostics Melanoma and MAPK Pathways

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JNCI Journal of the National Cancer Institute

Volume 84, Issue 23, pp. 1781-1788

DOI: 10.1093/jnci/84.23.1781

Field-Weighted Citation Impact: 10.31